Blog | HemaCare

HemaCare Leukopaks Support Novel Gene Editing Strategy

May 7, 2019 10:07:00 AM / by Nancy Andon, MSc posted in Leukopak, Stem Cells, Blood Disorders


In an independent publication [1] researchers at UCLA cited using leukopaks obtained from HemaCare in order to investigate a new gene editing method.

The group is researching strategies to treat genetic blood disorders such as sickle cell anemia. While there has been a great deal of research focused on using CRISPR/Cas9 gene therapy to treat these illnesses [2], current strategies for gene editing in hematopoietic stem cells are inefficient, and thus costly.

Read More

Stem Cells Working on Matters of the Heart

Apr 9, 2019 10:06:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cardiovascular Disease, heart disease, Stem Cells


After suffering from a heart attack, patients may eventually have a treatment option which uses their own stem cells to repair and restore heart muscle tissue.

According to the Centers for Disease control, over 600,000 people in the U.S. die yearly from heart disease, and 735,000 Americans have a heart attack each year. Acute myocardial infarction (heart attack) occurs when blood flow to the heart muscle is blocked leading to damage to the heart muscle tissue.  The heart tries to heal after an infarction, but this involves the formation of scar tissue that does not restore adequate function to the heart. The advancement of regenerative medicine using adult stem cells for cardiac tissue repair has the potential to provide a means to repair heart tissue in a way that returns full heart muscle cell function.

Read More

Can Stem Cells Be A Game Changer for MS Patients?

Apr 2, 2019 10:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Stem Cell Therapy, Stem Cells


Stem-cells and MS are widely discussed, but we might be finally getting closer to stem-cell treatments for MS patients.

Stem cell therapies are investigated for their potential to provide long-lasting or permanent remission of multiple sclerosis (MS) signs and symptoms. Many patients are well-informed of the potential of stem cell therapy for MS, and many seek treatments abroad that are promoted to give positive or curative outcomes. There are also clinics in the US that provide treatments that are outside of FDA-approved uses. The only FDA-approved, stem-cell based products used in the US consist of CD34+ stem cells derived from cord blood.

Read More

Developing Treatments for Sclerosis Patients

Mar 19, 2019 10:30:00 AM / by Stacy Matthews Branch, DVM, PhD posted in PBMCs, Stem Cells, immunosuppressive therapy


Systemic sclerosis, also called scleroderma, progressive systemic sclerosis, or CREST syndrome, is a rare autoimmune connective tissue disease with fibrosis and vasculopathy. Patients often have sclerotic, thickened skin, but some experience significant organ damage. Immunosuppressive therapy is a common approach to patients with systemic sclerosis, but there is a subset of patients that do not respond well to treatment.

Read More

HemaCare Immune Cells Facilitate Study on Gene Activation During Stem Cell Development

Jan 15, 2019 10:04:00 AM / by Nancy Andon, MSc posted in genes, Stem Cells


A recent independent study cites using HemaCare-sourced immune cells to investigate a protein involved in gene activation during hematopoietic stem cell (HSC) development. [1]

The study, published by scientists at the Yokohama Institute in Japan, is focused on the function of a protein known as RUNX1. The reason RUNX1 is of particular interest is that it’s implicated in the development of a number of different types of cancer, including breast cancer, skin cancer, and acute myeloid leukemia. [2] In the latter case, defects in the gene that codes for the RUNX1 protein disrupt stem cell differentiation. This means that instead of normal development into mature cell types, there is a massive build-up of blast cells in the bone marrow, which is the hallmark of leukemia. Scientists have known since 2001 [3] that the RUNX1 protein is involved in the differentiation of hematopoietic stem cells into mature blood cells. But in order to target RUNX1’s role in cancer development, researchers need a much more in-depth knowledge of exactly how the protein is exerting its function.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts